The latest price target for 89bio (NASDAQ:ETNB) was reported by Wolfe Research on February 4, 2025. The analyst firm set a price target for $0.00 expecting ETNB to fall to within 12 months (a possible -100.00% downside). 29 analyst firms have reported ratings in the last year.

The latest analyst rating for 89bio (NASDAQ:ETNB) was provided by Wolfe Research, and 89bio initiated their outperform rating.

The last upgrade for 89bio Inc happened on May 12, 2022 when Raymond James raised their price target to $12. Raymond James previously had an outperform for 89bio Inc.

The last downgrade for 89bio Inc happened on January 12, 2024 when RBC Capital changed their price target from N/A to $15 for 89bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 89bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 89bio was filed on February 4, 2025 so you should expect the next rating to be made available sometime around February 4, 2026.

While ratings are subjective and will change, the latest 89bio (ETNB) rating was a initiated with a price target of $0.00 to $0.00. The current price 89bio (ETNB) is trading at is $11.01, which is out of the analyst’s predicted range.